Get the Stockscreener App
0.2321
0.48%
0.0011
Virpax Pharmaceuticals Inc stock is traded at $0.2321, with a volume of 782.
It is up +0.48% in the last 24 hours and down -94.94% over the past month.
See More
Previous Close:
$0.231
Open:
$0.231
24h Volume:
782
Relative Volume:
7.82
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-13.24M
P/E Ratio:
-0.0263
EPS:
-8.83
Net Cash Flow:
$-16.85M
1W Performance:
+0.48%
1M Performance:
-94.94%
6M Performance:
-97.91%
1Y Performance:
-99.74%
1-Day Range:
$0.231
$0.2465
1-Week Range:
$0.231
$0.2465
52-Week Range:
$0.212
$0.2869
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Name
Virpax Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare VRPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2321 | 0 | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Virpax Pharmaceuticals Inc Stock (VRPX) Latest News
Best Nanotechnology Stocks To Follow Today – May 31st - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax and Nanomerics Enter Technology License Agreement for Developing A Product for PTSD Treatment - StatNano
Promising Nanotechnology Stocks To Watch Now – May 7th - The AM Reporter
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Up 5.5% – Here’s What Happened - Defense World
Virpax(R) Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel - ACCESS Newswire
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Increase in Short Interest - Defense World
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MSN
Virpax Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com India
Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Promising Nanotechnology Stocks To Watch NowMarch 22nd - MarketBeat
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com India
VRPX stock plunges to 52-week low of $0.12 amid market challenges - Investing.com Australia
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
VRPX stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com India
Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
Virpax Reports Positive Results From Dose Range Finding Study of Pain Relief Treatment in Beagle Dogs - MarketScreener
Virpax receives positive Probudur(TM) results for dose range study -March 18, 2025 at 05:34 pm EDT - Marketscreener.com
Virpax reports positive results in Probudur dog study By Investing.com - Investing.com Australia
Virpax reports positive results in Probudur dog study - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - StockTitan
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.18 By Investing.com - Investing.com Australia
Virpax Pharmaceuticals stock hits 52-week low at $0.18 - Investing.com
Nanotechnology Stocks To Follow Now – March 7th - Defense World
Virpax Looking To Use Met To Develop Intranasal Covid Vaccine -March 07, 2025 at 08:36 am EST - Marketscreener.com
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - The Bakersfield Californian
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - StockTitan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - StockTitan
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
Stock Market Update – Virpax Pharmaceuticals Stock Price Prediction 2025 - ldccbank
Virpax Pharmaceuticals Inc Stock (VRPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Cap:
|
Volume (24h):